IDWeek and HIV Glasgow 2016*

October 23-30, 2016; Glasgow, United Kingdom; New Orleans, Louisiana
Review the clinical impact of new HIV-related data presented at 2 scientific meetings in the fall of 2016: IDWeek and HIV Glasgow. This program includes Capsule Summaries, downloadable slidesets, and an expert analysis text module.

Clinical Impact


Previous DRV dose and baseline genotypic susceptibility score did not negatively affect the efficacy of switching from DRV-containing ART to EVG/COBI/TAF/FTC plus DRV.

Released: November 8, 2016

Switch to RPV/FTC/TAF from NNRTI/FTC/TDF-containing regimen associated with significant improvements in markers of renal and bone safety.

Released: November 10, 2016

Efficacy and safety outcomes were independent of third agent and at Week 48 were consistent in patients 50 years of age or older.

Released: November 17, 2016

Discontinuation for neuropsychiatric events more common for dolutegravir and comprised primarily sleep disturbances and insomnia; women, older adults, and patients initiating concurrent abacavir at increased risk.

Released: November 8, 2016

After 48 weeks, switch to DRV/RTV plus 3TC from DRV/RTV plus TDF/FTC or ABC/3TC was well tolerated and associated with maintenance of virologic suppression without emergent resistance.

Released: November 16, 2016

Four of 85 patients completing 24 weeks of dolutegravir treatment experienced virologic failure.

Released: November 17, 2016

Similar virologic efficacy observed across disease and demographic subgroups.

Released: November 16, 2016

Both regimens demonstrated high genetic barriers to resistance.

Released: November 23, 2016

Low rates of psychiatric adverse events in DTG/ABC/3TC and ATV/RTV plus TDF/FTC treatment arms.

Released: November 17, 2016

Insomnia was the most common dolutegravir-related psychiatric adverse event in all 4 examined trials.

Released: November 10, 2016
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Educational grant provided by:
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.